Rubicon Research IPO Review – Date, Price, GMP, Analysis, Should You Invest or Avoid?

Rubicon Research Limited is coming up with its Initial Public Offering (IPO) that opens on October 9, 2025, and closes on October 13, 2025. The issue comprises both a fresh issue of ₹500 crores and an offer for sale of ₹877.50 crores, aggregating up to ₹1,377.50 crores. Let us do a detailed Rubicon Research IPO Review, covering its issue details, dates, financials, strengths, risks, GMP, and valuation analysis, and find out whether you should invest or avoid this IPO.


About Rubicon Research Limited

Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations. The company’s portfolio includes 72 approved ANDA/NDA products by the US FDA, out of which 66 products are commercialized. Rubicon also has 17 new products under US FDA approval and 63 under development.

As of June 2025, Rubicon caters to over 96 customers across 350+ SKUs, including major US wholesalers and GPOs. It operates three manufacturing facilities in India and two US FDA-approved R&D centers in India and Canada.

The company has also expanded its presence to international markets including the UK, Australia, Singapore, Saudi Arabia, and UAE.

Rubicon Research IPO Review – Check IPO Date, Price, GMP, Issue Size, Financials, Analysis, and Expert View. Should you invest or avoid Rubicon Research IPO


Competitive Strengths

  • Fastest-growing Indian pharmaceutical player among peers.
  • Strong R&D foundation with robust data-driven formulation development.
  • Deep US market penetration – supplies to major wholesalers and pharmacies.
  • USFDA-approved facilities ensuring strong compliance.
  • Proven track record of profitability and growth.
  • Experienced leadership team with technical and business acumen.

Rubicon Research IPO Issue Details

Particulars Details
IPO Opening Date October 9, 2025
IPO Closing Date October 13, 2025
IPO Size ₹1,377.50 Crores
Fresh Issue ₹500 Crores
Offer for Sale (OFS) ₹877.50 Crores
Price Band ₹461 – ₹485 per share
Face Value ₹1 per share
Lot Size 30 Shares
Minimum Investment (Retail) ₹14,550
Listing Exchange BSE, NSE
Book Running Lead Managers Axis Capital, JM Financial, IIFL Capital, SBI Capital Markets
Registrar MUFG Intime India Pvt. Ltd.

Company Financials (Restated Consolidated)

Particulars (in ₹ Cr) FY23 FY24 FY25 Q1 FY26*
Total Income 419 872 1,296 357
PAT -16.9 91.0 134.4 43.3
EBITDA 43.9 173.1 267.9 79.7
Net Worth 286 385 541 594
Debt/Equity Ratio 0.73 0.73 0.73
PAT Margin -4.0% 10.4% 10.4% 12.1%

*As of June 30, 2025.

Key Metrics:

  • ROE: 29.02%
  • ROCE: 26.45%
  • EBITDA Margin: 20.67%

Objects of the Issue

The net proceeds from the fresh issue will be utilized for:

  1. Prepayment/repayment of certain outstanding borrowings – ₹3,100 million.
  2. Funding inorganic growth and strategic acquisitions.
  3. General corporate purposes.

Valuation – P/E Ratio vs Peers

Company CMP (₹) EPS (₹) P/E Remarks
Rubicon Research Ltd (at upper price) 485 8.7 55.7x Moderate
Sun Pharma 43.2 35x Established large-cap
Cipla 42.1 33x Strong domestic brand
Torrent Pharma 58.7 45x High-margin player
Industry Average 38x

👉 Rubicon’s P/E of ~55x seems on the higher side compared to the industry average, reflecting the company’s high growth expectation but relatively premium valuation.


Reasons to Invest in Rubicon Research IPO

  1. Rapidly expanding US generics footprint and diversified global presence.
  2. High margin and return ratios (ROE > 29%) indicate efficient capital use.
  3. Strong R&D pipeline with multiple products awaiting USFDA approval.
  4. Growing revenue and profits over the last three years.
  5. Debt reduction through IPO proceeds can improve profitability.
  6. Prominent institutional backing (General Atlantic Singapore) adds credibility.

Risk Factors in the IPO

  1. High dependence on US markets (90%+ revenues) – regulatory risks.
  2. Premium valuation compared to industry peers.
  3. Foreign exchange fluctuations can impact margins.
  4. Pending USFDA approvals can delay product launches.
  5. Highly competitive pharma sector with pricing pressures.
  6. Debt levels still moderately high post repayment.

Rubicon Research IPO GMP (Grey Market Premium)

As of October 5, 2025, the Rubicon Research IPO GMP is around ₹40-45 per share, indicating a listing gain of ~8-10% over the upper price band. However, GMPs tend to fluctuate until listing.


How to Apply for Rubicon Research IPO

You can apply for the Rubicon Research IPO through any of the following:

  1. ASBA facility – via your bank’s net banking portal (Axis, HDFC, SBI, ICICI, etc.)
  2. UPI-based applications through Zerodha, Groww, Upstox, Angel One, etc.
  3. Physical ASBA forms – available at bank branches.

Conclusion – Should You Invest in Rubicon Research IPO?

Rubicon Research is a high-growth pharma company with strong fundamentals, robust R&D capabilities, and expanding global reach. The company’s financial performance has been impressive, with consistent growth in profits and margins.

However, the valuation (P/E ~55x) appears expensive compared to peers, and the high dependence on the US market adds concentration risk.

My View: Moderate-risk investors with a long-term horizon may consider subscribing for listing gains and long-term growth, while conservative investors may wait for better valuations post-listing.


Frequently Asked Questions (FAQs)

1. What is Rubicon Research IPO date?
Rubicon Research IPO opens on October 9, 2025, and closes on October 13, 2025.

2. What is the Rubicon Research IPO price band?
The IPO price band is ₹461 to ₹485 per share.

3. What is the Rubicon Research IPO size?
The total issue size is ₹1,377.50 crores.

4. How much is the minimum investment for retail investors?
Retail investors can apply with a minimum of 1 lot (30 shares) worth ₹14,550.

5. What is the Rubicon Research IPO GMP today?
As of now, the Grey Market Premium (GMP) is around ₹40-45.

6. Who are the promoters of Rubicon Research?
Promoters include General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, and Sudhir Pilgaonkar.

7. Should you invest in Rubicon Research IPO?
Investors with medium-to-high risk appetite can consider for listing gains and long-term potential.


IPO Disclaimer

Investing in IPOs involves market risks. Please read the Red Herring Prospectus (RHP) carefully and consult your financial advisor before investing. The information on myinvestmentideas.com is for educational purposes only and not investment advice.

Suresh KP

Leave a Reply

Your email address will not be published. Required fields are marked *